Ascendis Pharma A (ASND) Current Deferred Revenue (2012 - 2025)

Ascendis Pharma A has disclosed Current Deferred Revenue across 14 years of filings, most recently posting $5.8 million for Q4 2025.

• Current Deferred Revenue for Q4 2025 came in at $5.8 million, up 475.38% year-over-year; the trailing twelve-month figure through Dec 2025 was $5.8 million (up 475.38% YoY), and the FY2025 annual result was $5.8 million, up 475.38% from the prior year.
• Current Deferred Revenue came in at $5.8 million for Q4 2025 at Ascendis Pharma A, up from $1.0 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $10.8 million in Q3 2022 to a low of -$10.1 million in Q3 2023.
• The 5-year median for Current Deferred Revenue is -$274775.5 (2023), against an average of $319607.1.
• Peak annual rise in Current Deferred Revenue reached 2904.72% in 2022, while the deepest fall reached 1895.76% in 2022.
• Ascendis Pharma A's Current Deferred Revenue stood at $6.0 million in 2021, then surged by 48.26% to $8.8 million in 2022, then plunged by 85.56% to $1.3 million in 2023, then fell by 21.49% to $1.0 million in 2024, then soared by 475.38% to $5.8 million in 2025.
• The last three Current Deferred Revenue figures came in at $5.8 million (Q4 2025), $1.0 million (Q4 2024), and -$600726.1 (Q3 2024), per Business Quant data.